CHARACTERIZATION OF SUBVISIBLE PARTICLES IN PROTEIN AND VIRAL VACCINES

Presented by Marina Kirkitadze, Head of Process Support & PAT Platform, Analytical Sciences at Sanofi Pasteur.
Followed by Bonnie Edwards, Product Manager of Imaging and MFI at ProteinSimple
The first topic of this webinar is the characterisation of visible and subvisible particles in protein and viral vaccine formulations. Visible and subvisible particles were found to be inherent to the product and were analyzed by several methods including MFI, DLS and PALS - Presented by Marina Kirkitadze
Followed by Characterizing Sub-Visible Particle Populations with Micro-Flow Imaging - Presented by Bonnie Edwards
Discussing the accurate determination of sub-visible particles and protein aggregates is important to ensure the safety and efficacy of biopharmaceutical formulations. As such, biopharmaceutical manufacturers are expected to characterize, monitor, and control sub-visible particles and protein aggregates in their products. Traditional techniques such as light obscuration often lack the sensitivity to distinguish translucent and potentially harmful protein aggregates. With imaging-based, direct particle detection, Micro-Flow Imaging (MFI) offers several advantages over traditional techniques, enabling the ability to detect and identify protein aggregates as well as other sub-visible contaminants. In this presentation, we will discuss how MFI provides particle count, size, and other morphological information in order to provide novel and unique insights into particle characterization and quantification in protein formulations.